Skip to main content

Amniotics AB (publ) (AMNI.ST)

Nasdaq Stockholm Healthcare BiotechnologyView data quality →
34.5Poor

ValueMarkers Composite Index

Top 1%#44,196 of 44,707

DCF data not available

Piotroski
3/9
Weak
Beneish
-
Altman
-7.65
Distress
DCF Value
-
N/A
ROIC
-160.5%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Amniotics AB (publ) (AMNI.ST) — VMCI valuation read

AMNI.ST prints VMCI 35/100 inside the Healthcare sector, where the median sits at 50. The 16-point below-median delta is the cleanest single-number summary of Amniotics AB (publ)'s composite stance, and in the mid-cap bucket it places the share behind the typical peer on the five-pillar mix.

On AMNI.ST, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** AMNI.ST trades at 22.0x earnings, 22% above the Healthcare median of 18.0x; that is the value line. ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 2.2x is the rate-sensitivity line to watch; that is the risk line for Amniotics AB (publ) on the trailing financials.

AMNI.ST fell 0.4% over the trailing 7 days, with a +5.7% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in AMNI.ST’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.